Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

William Keller

Physician Assistant North Port, FL Physician Assistant

NPI 1033259296 CMS profile 10544883

14400 Tamiami Trl, North Port, FL 34287

Open in the dashboard

General payments

$12,575

699 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Keller of North Port, FL is reported in the CMS Open Payments database as having received $12,575 across 699 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,776 100
2024 General $2,579 134
2023 General $2,872 150
2022 General $2,762 159
2021 General $2,585 156

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Keller
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to William Keller were reported at $1,776. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year William Keller Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,585 $132 $37–$438 $132
2022 $2,762 $155 $48–$522 $149
2023 $2,872 $167 $52–$557 $160
2024 $2,579 $178 $55–$600 $164
2025 $1,776 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,473 83 payments
  2. Lilly USA, LLC $1,035 63 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $850 33 payments
  4. Amgen Inc. $793 58 payments
  5. GlaxoSmithKline, LLC. $753 55 payments
  6. AbbVie, Inc. $735 38 payments
  7. Esperion Therapeutics, Inc. $656 33 payments
  8. Pfizer Inc. $632 34 payments
  9. Radius Health, Inc. $493 29 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $466 25 payments
  11. Other $4,687 248 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,575 699 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,420 80 payments
  2. RYBELSUS $1,320 74 payments
  3. Kerendia $850 33 payments
  4. TRELEGY ELLIPTA $708 50 payments
  5. NEXLETOL $656 33 payments
  6. MOUNJARO $584 32 payments
  7. NURTEC ODT $518 28 payments
  8. Otezla $505 40 payments
  9. ELIQUIS $435 23 payments
  10. Repatha $417 29 payments
  11. Other $10,684 595 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 78 drugs

Part D claims

3,351

Median for Physician Assistant: 241

Drug cost

$532,336

Median for Physician Assistant: $4,110

Branded share of claims

18.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 117 $179,390
Cosentyx Syringe Secukinumab Brand 11 $80,191
Mounjaro Tirzepatide Brand 43 $68,688
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 55 $38,568
Jardiance Empagliflozin Brand 27 $36,591
Eliquis Apixaban Brand 32 $29,602
Entresto Sacubitril/Valsartan Brand 19 $24,985
Xarelto Rivaroxaban Brand 13 $19,579
Myrbetriq Mirabegron Brand 17 $14,906
Trintellix Vortioxetine Hydrobromide Brand 11 $9,282

The 10 drugs with the highest cost, of 78 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $235
$235 — —
MOUNJARO
  • Lilly USA, LLC $186
$186 43 —
VRAYLAR
  • AbbVie, Inc. $178
$178 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $168
$168 55 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $110
  • PFIZER INC. $57
$167 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

699 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record